AIM Vaccine Co. Readies for mRNA Vaccine Trials

AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.

AIM Vaccine Co., Ltd. has announced the submission of pre-application for clinical trials of two mRNA vaccines targeting Respiratory Syncytial Virus and Shingles/Herpes Zoster. The move aligns with the company’s strategy to leverage mRNA technology and tackle diseases with significant market potential, as RSV vaccines are expected to hit aglobal marketsize of $16.7 billion by 2030, and Shingles vaccines may reach $23.9 billion. AIM Vaccine is at the forefront of mRNA vaccine development in China, with a robust R&D system and GMP-compliant production facilities poised to rapidly industrialize and commercialize these vaccines upon clinical approval.

For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.